JP2025512574A5 - - Google Patents

Info

Publication number
JP2025512574A5
JP2025512574A5 JP2024562060A JP2024562060A JP2025512574A5 JP 2025512574 A5 JP2025512574 A5 JP 2025512574A5 JP 2024562060 A JP2024562060 A JP 2024562060A JP 2024562060 A JP2024562060 A JP 2024562060A JP 2025512574 A5 JP2025512574 A5 JP 2025512574A5
Authority
JP
Japan
Prior art keywords
promoter
vector
bag3
polynucleotide
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024562060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512574A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/066054 external-priority patent/WO2023205767A2/en
Publication of JP2025512574A publication Critical patent/JP2025512574A/ja
Publication of JP2025512574A5 publication Critical patent/JP2025512574A5/ja
Pending legal-status Critical Current

Links

JP2024562060A 2022-04-22 2023-04-21 AAVベクターを使用するB細胞リンパ腫2関連Anthanogene 3 (BAG3)遺伝子治療 Pending JP2025512574A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263333798P 2022-04-22 2022-04-22
US63/333,798 2022-04-22
PCT/US2023/066054 WO2023205767A2 (en) 2022-04-22 2023-04-21 B-cell lymphoma 2–associated anthanogene 3 (bag3) gene therapy using aav vector

Publications (2)

Publication Number Publication Date
JP2025512574A JP2025512574A (ja) 2025-04-17
JP2025512574A5 true JP2025512574A5 (cg-RX-API-DMAC7.html) 2026-04-22

Family

ID=88420755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024562060A Pending JP2025512574A (ja) 2022-04-22 2023-04-21 AAVベクターを使用するB細胞リンパ腫2関連Anthanogene 3 (BAG3)遺伝子治療

Country Status (13)

Country Link
US (1) US20250269065A1 (cg-RX-API-DMAC7.html)
EP (1) EP4511048A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025512574A (cg-RX-API-DMAC7.html)
KR (1) KR20250012749A (cg-RX-API-DMAC7.html)
CN (1) CN119072323A (cg-RX-API-DMAC7.html)
AR (1) AR129122A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023258039A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248774A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003182A1 (cg-RX-API-DMAC7.html)
IL (1) IL316183A (cg-RX-API-DMAC7.html)
MX (1) MX2024012761A (cg-RX-API-DMAC7.html)
TW (1) TW202409285A (cg-RX-API-DMAC7.html)
WO (1) WO2023205767A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102673203B1 (ko) 2016-04-20 2024-06-10 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. Pklr의 유전자 발현 증강을 위한 조성물 및 방법
AU2018352583B2 (en) 2017-10-16 2025-04-17 Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. Lentiviral vectors for delivery of PKLR to treat Pyruvate Kinase Deficiency
US12539316B2 (en) 2018-04-11 2026-02-03 Spacecraft Seven, Llc Compositions and methods for stem cell transplant
IL280465B2 (en) 2018-07-30 2025-03-01 Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P Methods for gene modification of hematopoietic cells
WO2024215655A1 (en) * 2023-04-10 2024-10-17 Tenaya Therapeutics, Inc. Cardioprotective bag3 therapies
AU2024265705A1 (en) * 2023-05-02 2025-11-20 Research Institute At Nationwide Children's Hospital Gene therapy for treatment of protein misfolding diseases
WO2025235491A1 (en) * 2024-05-07 2025-11-13 Affinia Therapeutics Inc. Recombinant aav for treatment of cardiac diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007124578A1 (en) * 2006-04-27 2007-11-08 Universite De Montreal Assessment and reduction of risk of graft-versus-host disease
WO2015117010A2 (en) * 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 as a target for therapy of heart failure
EP4081643A1 (en) * 2019-12-24 2022-11-02 Asklepios Biopharmaceutical, Inc. Regulatory nucleic acid sequences
IL300187A (en) * 2020-08-05 2023-03-01 Spacecraft Seven Llc Gene therapy CSRP3 (protein 3 rich in cysteine and glycine)
CN116406297A (zh) * 2020-08-05 2023-07-07 阿斯克肋匹奥生物制药公司 治疗心脏疾患和充血性心力衰竭以及施用aav载体的方法

Similar Documents

Publication Publication Date Title
JP2023538519A5 (cg-RX-API-DMAC7.html)
US20240390519A1 (en) Plakophilin-2 (pkp2) gene therapy using aav vector
US20220331409A1 (en) Factor ix gene therapy
JP2024546103A5 (cg-RX-API-DMAC7.html)
JP2024523707A5 (cg-RX-API-DMAC7.html)
JP2023536618A5 (cg-RX-API-DMAC7.html)
JP2024545507A5 (cg-RX-API-DMAC7.html)
JP2023536921A5 (cg-RX-API-DMAC7.html)
JP2022520232A5 (cg-RX-API-DMAC7.html)
JP2023514242A5 (cg-RX-API-DMAC7.html)
JP2021533805A5 (cg-RX-API-DMAC7.html)
JP2023536902A5 (cg-RX-API-DMAC7.html)
JP2025505662A5 (cg-RX-API-DMAC7.html)
KR20250012749A (ko) Aav 벡터를 사용한 b-세포 림프종 2-관련 안타노겐 3(bag3) 유전자 요법
JP2023537903A5 (cg-RX-API-DMAC7.html)
JP2024545507A (ja) Aavベクターを用いたトロポニンc(tnnc1)遺伝子治療
JP2022533448A5 (cg-RX-API-DMAC7.html)
JP2024545183A5 (cg-RX-API-DMAC7.html)
JP2024514110A5 (cg-RX-API-DMAC7.html)
JP2022530264A5 (cg-RX-API-DMAC7.html)
RU2024134795A (ru) Генная терапия ассоциированным с в-клеточной лимфомой 2 антаногеном 3 (bag3) с использованием вектора aav
JP2025503868A5 (cg-RX-API-DMAC7.html)
JP2022514271A5 (cg-RX-API-DMAC7.html)
RU2024118474A (ru) Генная терапия в отношении юнктофилина-2 (jph2) с применением вектора на основе aav
RU2025121437A (ru) Генная терапия для плакофилина-2 (pkp2) с применением вектора на основе aav